Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan

AbuRuz, Salah; Alrashdan, Yazan; Jarab, Anan S.; Jaber, Deema; AlAwwa, Izzat

doi:10.1007/s11096-013-9806-8

Cited by 28 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The normalization of eGFR had an impact on drug dosing decisions; there was a higher level of agreement among the equations when the normalization to BSA was removed from the eGFR values. This aligns with the National Kidney Disease Education Program's suggested approach that either an eCrCl or an eGFR with BSA normalization removed is acceptable for drug dosing estimations …”

Section: Discussionsupporting

confidence: 53%

Comparison of equations for dosing of medications in renal impairment

et al. 2017

View full text Add to dashboard Cite

There is need for a long-term multi-centre study in a diverse population to define the clinical effects of the discrepancies among the equations for drug dosing. Given the greater concordance of the non-normalized CKD-EPI equation with the Cockcroft-Gault equation for dosing, the recommendation by Kidney Health Australia and the United States National Kidney Disease Education Program that 'dosing based on either eCrCl or an eGFR with body surface area normalization removed are acceptable' seems suitable and practicable for the purpose of dosing of non-critical drugs in the primary care setting.

show abstract

Section: Discussionsupporting

confidence: 53%

Comparison of equations for dosing of medications in renal impairment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Many studies reported pharmacists’ interventions in: modifying drug doses and recommending new pharmacotherapy; [ 16 , 19 , 21 – 23 , 25 – 27 , 29 , 30 , 32 – 40 , 52 , 59 ]; interacting with a member of the multidisciplinary team; [ 15 – 17 , 19 – 21 , 23 – 25 , 27 , 31 , 32 , 34 – 38 , 40 – 43 ] requesting and monitoring laboratory parameters; [ 15 , 23 , 25 , 27 , 33 , 34 , 36 , 37 , 43 ] assessing appropriateness of medications prescribed for hospitalised patients at each point of care; [ 17 , 22 , 29 , 30 , 35 – 38 , 40 , 57 ]. Fewer studies described pharmacist processes at out-patient, pharmacist-led clinics relating to the management of specific CKD complications, such as anaemia; [ 34 , 39 , 44 ] hypertension and diabetes; [ 54 ] managing hypertension through telemedicine; [ 41 ] optimising dyslipidaemia management; [ 37 , 45 ] improving haemoglobin A1c levels (HbA1c); [ 43 ] and emphasising smoking cessation. [ 37 , 43 ] Development of protocols and compiling and updating guidelines were also described in two studies [ 22 , 34 ].…”

Section: Resultsmentioning

confidence: 99%

“…Fewer studies described pharmacist processes at out-patient, pharmacist-led clinics relating to the management of specific CKD complications, such as anaemia; [ 34 , 39 , 44 ] hypertension and diabetes; [ 54 ] managing hypertension through telemedicine; [ 41 ] optimising dyslipidaemia management; [ 37 , 45 ] improving haemoglobin A1c levels (HbA1c); [ 43 ] and emphasising smoking cessation. [ 37 , 43 ] Development of protocols and compiling and updating guidelines were also described in two studies [ 22 , 34 ]. Performing medication reconciliation [ 46 ]; providing patient medication counselling, education on disease status or medication, conducting motivational interviews to improve adherence were also reported [ 15 , 25 , 27 , 29 , 30 , 34 , 36 , 37 , 42 , 43 , 47 – 50 , 55 , 57 , 58 , 60 ].…”

Section: Resultsmentioning

confidence: 99%

“…[ 37 , 43 ] Development of protocols and compiling and updating guidelines were also described in two studies [ 22 , 34 ]. Performing medication reconciliation [ 46 ]; providing patient medication counselling, education on disease status or medication, conducting motivational interviews to improve adherence were also reported [ 15 , 25 , 27 , 29 , 30 , 34 , 36 , 37 , 42 , 43 , 47 – 50 , 55 , 57 , 58 , 60 ]. A number of studies reported pharmacists’ participation in ward rounds [ 17 , 22 , 35 , 37 , 38 , 40 ], providing educational sessions to healthcare professionals [ 22 , 34 ] and performing activities such as medication use evaluations [ 34 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review

et al. 2019

View full text Add to dashboard Cite

Background Clinical pharmacy services have potential to contribute significantly to the multidisciplinary team providing safe, effective and economic care for patients. Given recent practice developments (e.g. polypharmacy reviews and pharmacist prescribing) there is a need to provide a current synthesis of the evidence base for characteristics and outcomes of clinical pharmacy practice in chronic kidney disease patients. Aim of the review To critically appraise, synthesise and present the available evidence of the characteristics (structures and processes) and outcomes of clinical pharmacy practice as part of the multidisciplinary care of patients with chronic kidney disease. Method PubMed, International Pharmaceutical Abstracts (IPA), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medline and Scopus were searched for peer reviewed papers using improved search strategy. Included studies were quality assessed using Downs and Black tool for controlled studies and the mixed methods appraisal tool for all controlled and non-controlled studies. Data were extracted and synthesised using a narrative approach. Screening, quality assessment and data extraction were performed by two independent researchers. Ethics approval was not required. Results Forty-seven studies were identified from a variety of countries, with 31 based in a hospital setting. Controlled study designs were employed in 20, with only ten of these using randomisation. Resources available for service provision were poorly reported in all papers. Positive impact on clinical outcomes included significant improvement in parathyroid hormone, blood pressure, haemoglobin and creatinine clearance. Pharmacists identified 5302 drug related problems in 2933 patients and made 3160 recommendations with acceptance rates up to 95%. Impact on humanistic outcomes was shown through improvement in health related quality of life and patient satisfaction. Economic benefits arose from significant cost savings through pharmaceutical care provision. Conclusion While there is some evidence of positive impact on clinical, humanistic and economic outcomes, this evidence is generally of low quality and insufficient volume. While the existing evidence is in favour of pharmacists’ involvement in the multidisciplinary team providing care to patients with chronic kidney disease, more high-quality research is warranted. Electronic supplementary material The online version of this article (10.1007/s11096-019-00816-4) contains supplementary material, which is available to authorized users.

show abstract

“…Despite the recent recognition of the benefits of PCSs, its implementation in patient care settings to achieve quality service remains a challenge. 5 , 6 , 12 , 22 – 24 Knowing that one of the major stakeholders of PCSs is the patient, patients’ awareness and demands of the service should be reflected to develop such services.…”

Section: Discussionmentioning

confidence: 99%

Satisfaction and expressed needs of pharmaceutical care services and challenges recognized by patients in South Korea

Kang¹,

Rhew²,

Oh³

et al. 2017

PPA

View full text Add to dashboard Cite

PurposeTo assess the degree of satisfaction and expressed needs of pharmaceutical care services in patients with chronic diseases and explore the factors related to the needs from patients’ perspectives for the further development of pharmaceutical care service models.Patients and methodsA cross-sectional survey of 220 patients (mean age ± SD: 61.3±13.1, male:female: 104:116) was conducted. The questionnaire was structured to measure patients’ degree of satisfaction and expressed needs using a 5-point Likert scale. Additionally, preferred duration, methods of service delivery, and willingness to pay were surveyed. Responses were analyzed using an ordinal regression method to predict factors that were related to pharmaceutical care services.ResultsSixty-seven patients had experienced pharmaceutical care services. Their satisfaction levels were high in all categories; however, there were no significant differences between categories. The levels of expressed needs were similar among categories without significant differences. The preferred delivery method was a face-to-face conversation combined with being provided with written information (53.2%). The preferred duration was ≤10 min (70.5%). About 48% of the patients showed willingness to pay for the service. Education level and region influenced patients’ needs.ConclusionThe satisfaction and needs of pharmaceutical care services was very positive; however, noticing only a third of patients experienced pharmaceutical care services, this may indicate a lack of awareness and less appreciation of pharmacists by patients. Details concerning patients’ awareness and the value of pharmaceutical care services require further investigation.

show abstract

Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan

Cited by 28 publications

References 20 publications

Comparison of equations for dosing of medications in renal impairment

Comparison of equations for dosing of medications in renal impairment

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review

Satisfaction and expressed needs of pharmaceutical care services and challenges recognized by patients in South Korea

Contact Info

Product

Resources

About